Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stan Kaye

Showing results (21-30 of 46) with videos related to

Pageof 5
Sort By:
Oncology|January 27, 2009
Clinical benefit of new targeted agents in phase I trials in patients with advanced colorectal cancerHendrik-Tobias Arkenau, Andre T Brunetto, Jorge Barriuso, et al.
British Journal of Cancer|August 23, 2017
RNAi screen reveals synthetic lethality between cyclin G-associated kinase and FBXW7 by inducing aberrant mitosesSaoirse O Dolly, Mark D Gurden, Konstantinos Drosopoulos, et al.
Gynecologic Oncology|July 7, 2007
Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trialsMichelle L Harrison, Martin E Gore, David Spriggs, et al.
Gynecologic Oncology|August 31, 2015
Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC)Heike Seifert, Alexandros Georgiou, Helen Alexander, et al.
European Journal of Cancer (Oxford, England : 1990)|June 14, 2008
90-Days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial?Hendrik-Tobias Arkenau, David Olmos, Joo Ern Ang, et al.
The Lancet. Oncology|December 11, 2002
Chemotherapy for metastatic breast cancer-report of a European expert panelJohn Crown, Véronique Diéras, Manfred Kaufmann, et al.
Molecular Cancer Therapeutics|September 19, 2007
The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivoLesley-Ann Martin, Julia E Head, Sunil Pancholi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2011
Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?Sophie Postel-Vinay, Carlos Gomez-Roca, L Rhoda Molife, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation studyWim W Ten Bokkel Huinink, Jozef Sufliarsky, Willem M Smit, et al.
Medical Oncology (Northwood, London, England)|February 12, 2013
Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trialsJosé María del Campo, Cristiana Sessa, Carolyn N Krasner, et al.
Pageof 5

Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
Oncology|January 27, 2009
Clinical benefit of new targeted agents in phase I trials in patients with advanced colorectal cancerHendrik-Tobias Arkenau, Andre T Brunetto, Jorge Barriuso, et al.
British Journal of Cancer|August 23, 2017
RNAi screen reveals synthetic lethality between cyclin G-associated kinase and FBXW7 by inducing aberrant mitosesSaoirse O Dolly, Mark D Gurden, Konstantinos Drosopoulos, et al.
Gynecologic Oncology|July 7, 2007
Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trialsMichelle L Harrison, Martin E Gore, David Spriggs, et al.
Gynecologic Oncology|August 31, 2015
Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC)Heike Seifert, Alexandros Georgiou, Helen Alexander, et al.
European Journal of Cancer (Oxford, England : 1990)|June 14, 2008
90-Days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial?Hendrik-Tobias Arkenau, David Olmos, Joo Ern Ang, et al.
The Lancet. Oncology|December 11, 2002
Chemotherapy for metastatic breast cancer-report of a European expert panelJohn Crown, Véronique Diéras, Manfred Kaufmann, et al.
Molecular Cancer Therapeutics|September 19, 2007
The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivoLesley-Ann Martin, Julia E Head, Sunil Pancholi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2011
Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?Sophie Postel-Vinay, Carlos Gomez-Roca, L Rhoda Molife, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation studyWim W Ten Bokkel Huinink, Jozef Sufliarsky, Willem M Smit, et al.
Medical Oncology (Northwood, London, England)|February 12, 2013
Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trialsJosé María del Campo, Cristiana Sessa, Carolyn N Krasner, et al.
Pageof 5